ZOFRAN ondansetron (as hydrochloride dihydrate) 8mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

zofran ondansetron (as hydrochloride dihydrate) 8mg tablet blister pack

aspen pharmacare australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 10 mg (equivalent: ondansetron, qty 8 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; iron oxide yellow; hypromellose - ondansetron (tablets, syrup, wafers, suppository and injection) is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy

ZOFRAN ondansetron (as hydrochloride dihydrate) 4mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

zofran ondansetron (as hydrochloride dihydrate) 4mg tablet blister pack

aspen pharmacare australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 5 mg (equivalent: ondansetron, qty 4 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; iron oxide yellow; hypromellose - ondansetron (tablets, syrup, wafers, suppository and injection) is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy

VARENAPIX 0.5 mg varenicline (as tartrate) tablets and 1.0 mg varenicline (as tartrate) tablets composite blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

varenapix 0.5 mg varenicline (as tartrate) tablets and 1.0 mg varenicline (as tartrate) tablets composite blister pack

arrotex pharmaceuticals pty ltd - varenicline tartrate, quantity: 1.71 mg (equivalent: varenicline, qty 1 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; hypromellose; triacetin; hyprolose; titanium dioxide; indigo carmine aluminium lake; sodium stearylfumarate; croscarmellose sodium - varenicline tablets are indicated as an aid to smoking cessation in adults over the age of 18 years.

VARENAPIX 1 mg varenicline (as tartrate) tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

varenapix 1 mg varenicline (as tartrate) tablets blister pack

arrotex pharmaceuticals pty ltd - varenicline tartrate, quantity: 1.71 mg (equivalent: varenicline, qty 1 mg) - tablet, film coated - excipient ingredients: hyprolose; titanium dioxide; hypromellose; triacetin; calcium hydrogen phosphate; indigo carmine aluminium lake; croscarmellose sodium; sodium stearylfumarate - varenicline tablets are indicated as an aid to smoking cessation in adults over the age of 18 years.

VARENAPIX 1 mg varenicline (as tartrate) tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

varenapix 1 mg varenicline (as tartrate) tablets bottle

arrotex pharmaceuticals pty ltd - varenicline tartrate, quantity: 1.71 mg (equivalent: varenicline, qty 1 mg) - tablet, film coated - excipient ingredients: hyprolose; titanium dioxide; hypromellose; triacetin; calcium hydrogen phosphate; indigo carmine aluminium lake; croscarmellose sodium; sodium stearylfumarate - varenicline tablets are indicated as an aid to smoking cessation in adults over the age of 18 years.

METEX XR metformin hydrochloride 500 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

metex xr metformin hydrochloride 500 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; povidone; hypromellose - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

METEX XR metformin hydrochloride 1000 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

metex xr metformin hydrochloride 1000 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; povidone; magnesium stearate; colloidal anhydrous silica - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

FAMPYRA fampridine 10mg modified release tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

fampyra fampridine 10mg modified release tablets bottle

biogen australia pty ltd - fampridine, quantity: 10 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; hypromellose; titanium dioxide; macrogol 400 - fampyra modified release tablets are indicated for the symptomatic improvement of walking ability in adult patients with multiple sclerosis who have shown improvement after 8 weeks of treatment

NITYR nitisinone 5 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

nityr nitisinone 5 mg tablet bottle

orpharma pty ltd - nitisinone, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; glycerol dibehenate - nityr tablets (nitisinone) are indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

NITYR nitisinone 2 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

nityr nitisinone 2 mg tablet bottle

orpharma pty ltd - nitisinone, quantity: 2 mg - tablet - excipient ingredients: lactose monohydrate; glycerol dibehenate - nityr tablets (nitisinone) are indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.